- Home
- SND vs MSLE Comparison
SND vs MSLE Comparison
Compare SND & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SND | MSLE |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Canada |
| Employees | 318 | 17 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 146.9M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SND | MSLE |
|---|---|---|
| Price | $5.21 | $7.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 398.1K | 105.2K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $166.67 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $1.76 | $6.67 |
| 52 Week High | $5.59 | $13.39 |
Technical Indicators
Market Signals| Indicator | SND | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 68.80 | 29.87 |
| Support Level | $1.92 | $6.67 |
| Resistance Level | $5.59 | $8.37 |
| Average True Range (ATR) | 0.21 | 0.83 |
| MACD | 0.14 | -0.21 |
| Stochastic Oscillator | 89.20 | 8.18 |
Price Performance
Historical ComparisonAbout SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.